Company Overview - YD Biopharma Limited is a clinical-stage biopharmaceutical company focused on cancer prevention medical diagnostics and the development of exosome-based therapeutics aimed at addressing diseases with high unmet medical needs [6] - The company has established itself as a recognized supplier of clinical trial drugs and is also developing post-market auxiliary products [6] Business Combination Details - Breeze Holdings Acquisition Corp. announced the approval of its business combination with YD Biopharma, with stockholders voting overwhelmingly in favor (3,127,474 shares for, 1,000 against, and 21 abstentions) [3] - The combined entity will operate under the name YD Bio Limited and is expected to trade on Nasdaq with the ticker symbol "YDES" [4] - The transaction is anticipated to close within the next two weeks, pending customary closing conditions [4] Advisors Involved - Legal and financial advisors for the transaction include ArentFox Schiff LLP for YD Biopharma, I-Bankers Securities, Inc. for Breeze, and Woolery & Co. PLLC for Breeze [5]